Literature DB >> 11095822

Leishmaniasis at the End of the Millennium.

.   

Abstract

The term leishmaniasis refers to the spectrum of disease caused by Leishmania species. The clinical manifestations of leishmaniasis depend on complex interactions between the virulence characteristics of the infecting Leishmania species and the genetically determined cell-mediated immune responses of its mammalian host. Leishmaniasis comprises three major syndromes: cutaneous, mucosal, and visceral. Variations exist within each syndrome.

Entities:  

Year:  1999        PMID: 11095822     DOI: 10.1007/s11908-999-0057-8

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  38 in total

1.  Short report: outbreak of cutaneous leishmaniasis in a nonimmune population of soldiers in Wadi Araba, Jordan.

Authors:  S Khoury; E K Saliba; O Y Oumeish
Journal:  Am J Trop Med Hyg       Date:  1999-04       Impact factor: 2.345

2.  Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.

Authors:  J D Berman; R Badaro; C P Thakur; K M Wasunna; K Behbehani; R Davidson; F Kuzoe; L Pang; K Weerasuriya; A D Bryceson
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

3.  Epidemiologic characterization of American cutaneous leishmaniasis in an endemic region of eastern Venezuela.

Authors:  A Jorquera; E Ledezma; L De Sousa; A Garcia; J Sanchez; J Zerpa; R Gonzalez; J A O'Daly
Journal:  Am J Trop Med Hyg       Date:  1998-05       Impact factor: 2.345

Review 4.  Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years.

Authors:  J D Berman
Journal:  Clin Infect Dis       Date:  1997-04       Impact factor: 9.079

5.  A nested-PCR-based schizodeme method for identifying Leishmania kinetoplast minicircle classes directly from clinical samples and its application to the study of the epidemiology of Leishmania tropica in Pakistan.

Authors:  H A Noyes; H Reyburn; J W Bailey; D Smith
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

6.  Regulator and effector functions of T-cell subsets in human Leishmania infections.

Authors:  M Kemp
Journal:  APMIS Suppl       Date:  1997

7.  Ecological interactions of visceral leishmaniasis in the state of Bahia, Brazil.

Authors:  I A Sherlock
Journal:  Mem Inst Oswaldo Cruz       Date:  1996 Nov-Dec       Impact factor: 2.743

8.  Towards a kala azar risk map for Sudan: mapping the potential distribution of Phlebotomus orientalis using digital data of environmental variables.

Authors:  M C Thomson; D A Elnaiem; R W Ashford; S J Connor
Journal:  Trop Med Int Health       Date:  1999-02       Impact factor: 2.622

9.  Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond.

Authors:  E A Khalil; A M el Hassan; E E Zijlstra; F A Hashim; M E Ibrahim; H W Ghalib; M S Ali
Journal:  Ann Trop Med Parasitol       Date:  1998-03

10.  Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources.

Authors:  J Seaman; A J Mercer; H E Sondorp; B L Herwaldt
Journal:  Ann Intern Med       Date:  1996-04-01       Impact factor: 25.391

View more
  3 in total

1.  New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.

Authors:  Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

2.  Reduced pathology following infection with transgenic Leishmania major expressing murine CD40 ligand.

Authors:  Ann E Field; Sagie Wagage; Sean M Conrad; David M Mosser
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

Review 3.  Leishmaniasis-HIV coinfection: current challenges.

Authors:  José Angelo Lauletta Lindoso; Mirella Alves Cunha; Igor Thiago Queiroz; Carlos Henrique Valente Moreira
Journal:  HIV AIDS (Auckl)       Date:  2016-10-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.